loading
Precedente Chiudi:
$2.95
Aprire:
$2.96
Volume 24 ore:
171.74K
Relative Volume:
0.27
Capitalizzazione di mercato:
$47.62M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-0.4737
EPS:
-6.1852
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
-5.79%
1M Prestazione:
-6.98%
6M Prestazione:
-50.84%
1 anno Prestazione:
-83.87%
Intervallo 1D:
Value
$2.93
$3.05
Intervallo di 1 settimana:
Value
$2.8037
$3.13
Portata 52W:
Value
$2.265
$26.05

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name
Nome
Jasper Therapeutics Inc
Name
Telefono
(650) 549-1400
Name
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Name
Dipendente
64
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
JSPR's Discussions on Twitter

Confronta JSPR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
JSPR
Jasper Therapeutics Inc
2.93 47.62M 0 -64.47M -52.33M -6.1852
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-08 Downgrade BMO Capital Markets Outperform → Market Perform
2025-07-08 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-07-07 Downgrade Cantor Fitzgerald Overweight → Neutral
2025-07-07 Downgrade William Blair Outperform → Mkt Perform
2025-02-13 Iniziato UBS Buy
2024-12-06 Iniziato BMO Capital Markets Outperform
2024-09-09 Iniziato JMP Securities Mkt Outperform
2024-07-08 Iniziato BTIG Research Buy
2024-06-27 Iniziato Stifel Buy
2024-05-06 Iniziato H.C. Wainwright Buy
2024-04-03 Iniziato Evercore ISI Outperform
2024-03-28 Iniziato RBC Capital Mkts Outperform
2024-03-18 Iniziato TD Cowen Outperform
2023-08-11 Iniziato CapitalOne Overweight
2022-02-28 Iniziato Cantor Fitzgerald Overweight
2021-11-08 Iniziato Credit Suisse Outperform
2021-10-21 Iniziato William Blair Outperform
2021-10-20 Iniziato BMO Capital Markets Outperform
2021-10-13 Iniziato Oppenheimer Outperform
Mostra tutto

Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie

pulisher
Aug 19, 2025

Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures - MSN

Aug 19, 2025
pulisher
Aug 18, 2025

HC Wainwright Issues Pessimistic Outlook for JSPR Earnings - Defense World

Aug 18, 2025
pulisher
Aug 18, 2025

Q3 EPS Forecast for Jasper Therapeutics Reduced by Analyst - Defense World

Aug 18, 2025
pulisher
Aug 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper - Bluefield Daily Telegraph

Aug 17, 2025
pulisher
Aug 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.

Aug 17, 2025
pulisher
Aug 17, 2025

UBS Group Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price - Defense World

Aug 17, 2025
pulisher
Aug 17, 2025

Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75 - Defense World

Aug 17, 2025
pulisher
Aug 15, 2025

UBS Cuts Price Target on Jasper Therapeutics to $25 From $29, Maintains Buy Rating - MarketScreener

Aug 15, 2025
pulisher
Aug 15, 2025

A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $12 to $25 - 富途牛牛

Aug 15, 2025
pulisher
Aug 15, 2025

Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays, Competitive Pressures - AInvest

Aug 15, 2025
pulisher
Aug 14, 2025

Jasper Therapeutics' Promising Clinical Data and Strategic Focus Earn Buy Rating - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks By Investing.com - Investing.com India

Aug 14, 2025
pulisher
Aug 14, 2025

Jasper Therapeutics’ SWOT analysis: briquilimab’s promise amid setbacks - Investing.com

Aug 14, 2025
pulisher
Aug 14, 2025

Jasper Therapeutics Reports Promising Q2 2025 Results - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

BTIG reiterates Buy rating on Jasper Therapeutics stock with $20 price target - Investing.com Canada

Aug 14, 2025
pulisher
Aug 14, 2025

JMP reiterates Market Outperform rating on Jasper Therapeutics stock By Investing.com - Investing.com Canada

Aug 14, 2025
pulisher
Aug 14, 2025

Jasper Reports Wider Loss in Fiscal Q2 - AOL.com

Aug 14, 2025
pulisher
Aug 13, 2025

Jasper Therapeutics shares fall 4.65% after-hours following Q2 2025 earnings report. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Jasper Reports Wider Loss in Fiscal Q2 - The Motley Fool

Aug 13, 2025
pulisher
Aug 13, 2025

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33) - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

Assessing Jasper Therapeutics' Earnings Miss and Clinical Pipeline Momentum in a High-Risk, High-Reward Biotech Play - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Jasper Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 13, 2025
pulisher
Aug 13, 2025

Jasper Therapeutics shares rise 3.51% intraday after Metagenomi reported positive business updates and financial results. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Jasper Therapeutics under investigation for alleged securities fraud. - AInvest

Aug 13, 2025
pulisher
Aug 12, 2025

Jasper Therapeutics shares rise 5.70% intraday after Metagenomi appoints Laurence Reid, PhD to its Board of Directors. - AInvest

Aug 12, 2025
pulisher
Aug 11, 2025

Jasper Therapeutics Inc (JSPR) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Aug 11, 2025
pulisher
Aug 11, 2025

How does the Q2 2025 earnings report affect JSPR's stock price? - AInvest

Aug 11, 2025
pulisher
Aug 10, 2025

Jasper Therapeutics (JSPR) Projected to Post Quarterly Earnings on Tuesday - Defense World

Aug 10, 2025
pulisher
Aug 10, 2025

Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated by Analysts at EF Hutton Acquisition Co. I - 富途牛牛

Aug 10, 2025
pulisher
Aug 09, 2025

Jasper Therapeutics WRT JSPRW Q2 2025 Earnings Preview Downside Expected Amid Technical Integration Hurdles - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Jasper Therapeutics JSPR 2025Q2 Earnings Preview Downside Ahead on Technical Challenges and Report Compilation Errors - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace

Aug 09, 2025
pulisher
Aug 08, 2025

Jasper Therapeutics Inc expected to post a loss of $1.33 a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 06, 2025

Jasper Therapeutics shares fall 3.02% intraday after Pomerantz Law Firm investigates claims of securities fraud. - AInvest

Aug 06, 2025
pulisher
Aug 01, 2025

What is the risk reward ratio of investing in Jasper Therapeutics Inc. Equity Warrant stockBest Dividend Data Feed Backed By Experts - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

What are the latest earnings results for Jasper Therapeutics Inc.Smart Portfolio Planner With Proven Results - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

Press Release: Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛

Aug 01, 2025
pulisher
Aug 01, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.

Aug 01, 2025
pulisher
Jul 31, 2025

What catalysts could drive Jasper Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - Jammu Links News

Jul 31, 2025
pulisher
Jul 31, 2025

What are the technical indicators suggesting about Jasper Therapeutics Inc. Equity WarrantStock Strategy Review For Beginners - Jammu Links News

Jul 31, 2025
pulisher
Jul 28, 2025

What is the dividend policy of Jasper Therapeutics Inc. Equity Warrant stockGet ahead with breakthrough trading ideas - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

What is Jasper Therapeutics Inc. company’s growth strategyPre Market Picks With High Returns - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Jasper Therapeutics Inc. Equity Warrant stock in 2025Top Growth Alerts With Proven Results - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

What makes Jasper Therapeutics Inc. stock price move sharplyPost Market Picks With Low Risk - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

How does Jasper Therapeutics Inc. Equity Warrant generate profit in a changing economySmart Portfolio Signals To Watch Now - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is Jasper Therapeutics Inc. stock overvalued or undervaluedAchieve rapid portfolio growth with expert help - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

What is the risk reward ratio of investing in Jasper Therapeutics Inc. stockCapitalize on market trends early - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

What are Jasper Therapeutics Inc. Equity Warrant company’s key revenue driversRapidly expanding wealth - Jammu Links News

Jul 28, 2025
pulisher
Jul 28, 2025

Should I hold or sell Jasper Therapeutics Inc. stock in 2025Free Stock Selection - Jammu Links News

Jul 28, 2025

Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Jasper Therapeutics Inc Azioni (JSPR) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Mahal Jeetinder Singh
Chief Operating Officer
Dec 12 '24
Sale
22.11
900
19,899
25,009
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Capitalizzazione:     |  Volume (24 ore):